These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25759014)

  • 21. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.
    Sánchez-Danés A; Larsimont JC; Liagre M; Muñoz-Couselo E; Lapouge G; Brisebarre A; Dubois C; Suppa M; Sukumaran V; Del Marmol V; Tabernero J; Blanpain C
    Nature; 2018 Oct; 562(7727):434-438. PubMed ID: 30297799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice.
    Khoo AB; Ali FR; Lear JT
    Curr Opin Oncol; 2016 Mar; 28(2):180-4. PubMed ID: 26780190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New perspectives in the management of basal cell carcinoma.
    Martín-Gorgojo A; Pastushenko I
    Actas Dermosifiliogr; 2014 Nov; 105(9):874-5. PubMed ID: 24934656
    [No Abstract]   [Full Text] [Related]  

  • 24. Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma.
    Khalid B; Mukherjee S; Ibrahimi S; Cannon T; Gilles E; Moreau A; Razaq M
    Am J Ther; 2018; 25(3):e394-e396. PubMed ID: 29557803
    [No Abstract]   [Full Text] [Related]  

  • 25. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion.
    Papastefanou VP; René C
    Ophthalmic Plast Reconstr Surg; 2017; 33(3S Suppl 1):S68-S70. PubMed ID: 26398246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma.
    Deng M; Marsch AF; Petronic-Rosic V
    Skinmed; 2017; 15(4):265-268. PubMed ID: 28859735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hedgehog signaling in basal cell carcinoma.
    Otsuka A; Levesque MP; Dummer R; Kabashima K
    J Dermatol Sci; 2015 May; 78(2):95-100. PubMed ID: 25766766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sonidegib phosphate: new approval for basal cell carcinoma.
    Tibes R
    Drugs Today (Barc); 2016 May; 52(5):295-303. PubMed ID: 27376162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neglected skin carcinomas and Vismodegib: our experience.
    Russo F; Mancini V; Taddeucci P; Cirocco A; Cusano F; Pellegrino M; Sirna R
    G Ital Dermatol Venereol; 2019 Oct; 154(5):597-599. PubMed ID: 29417798
    [No Abstract]   [Full Text] [Related]  

  • 34. Vismodegib in advanced basal-cell carcinoma.
    Babacan T; Sarici F; Altundag K
    N Engl J Med; 2012 Sep; 367(10):969-70; author reply 970. PubMed ID: 22931270
    [No Abstract]   [Full Text] [Related]  

  • 35. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.
    Dréno B; Kunstfeld R; Hauschild A; Fosko S; Zloty D; Labeille B; Grob JJ; Puig S; Gilberg F; Bergström D; Page DR; Rogers G; Schadendorf D
    Lancet Oncol; 2017 Mar; 18(3):404-412. PubMed ID: 28188086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vismodegib granted FDA approval for treatment of basal cell carcinoma.
    Oncology (Williston Park); 2012 Feb; 26(2):174, 213. PubMed ID: 22489352
    [No Abstract]   [Full Text] [Related]  

  • 38. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 39. Biochemical characterization of smoothened receptor antagonists by binding kinetics against drug-resistant mutant.
    Shimizu Y; Ishii T; Ogawa K; Sasaki S; Matsui H; Nakayama M
    Eur J Pharmacol; 2015 Oct; 764():220-227. PubMed ID: 26048307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.